| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8949221 | Journal of Geriatric Oncology | 2018 | 7 Pages |
Abstract
Even though frequency and patterns of IrAEs are different from pivotal studies, these results don't seem specific to older patients. Further prospective investigations are needed to better characterize and predict the impact of Nivolumab on older patients with NSCLC.
Keywords
ECoGCMIMetastatic non-small cell lung cancerPharmacovigilanceIRAEADRSAENivolumabFFPEPFsSafetyprogression-free survivaloverall survivalOlder patientsNSCLCNon-small cell lung cancereastern cooperative oncology groupAdverse drug reactionSerious adverse eventimmune-related adverse eventformalin-fixed paraffin-embedded
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Renaud Sabatier, Emanuel Nicolas, Maria Paciencia, Annie-Pierre Jonville-Béra, Anne Madroszyk, Maud Cecile, Cecile Braticevic, Ségolène Duran, Louis Tassy, Franck Rouby, Joëlle Micallef, Frédérique Rousseau,